MEDIROM Healthcare Technologies Inc. amended its Loan Agreement and Share Pledge Agreement to refinance JPY 275,000,000 in maturing convertible corporate bonds into additional debt. The amendment, dated July 14, 2026, increased the total principal amount of the loan from Kufu Company Holdings Inc. to JPY 475,000,000 and expanded the share pledge collateral covering MEDIROM MOTHER Labs Inc. shares to secure the refinanced obligations. The company operates in the healthcare technology industry.

Medirom Healthcare Technologies Inc. received a notice from Nasdaq stating it is not in compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 20-F for the fiscal year ended December 31, 2025. Although initially granted until July 27, 2026, to submit a compliance plan, Nasdaq has extended the deadline to November 11, 2026, for the company to regain compliance by filing the report. Failure to meet this new deadline will result in delisting proceedings, which the company may appeal. Medirom Healthcare Technologies Inc. operates in the healthcare technology industry, providing digital health solutions and remote patient monitoring services.

On June 25, 2026, MEDIROM Healthcare Technologies Inc. subsidiary MEDIROM MOTHER Labs Inc. announced it received an additional order from the 8th Division of the Japan Ground Self-Defense Force (JGSDF). The order is for the REMONY® remote health monitoring system, which incorporates the MOTHER Bracelet® charge-free smart tracker. The company operates in the healthcare technology industry, providing remote health monitoring solutions.